Jul 30
|
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
|
Jul 30
|
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
|
Jul 30
|
Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL
|
Jul 30
|
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
|
Jul 30
|
AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings
|
Jul 29
|
AbbVie (ABBV) Files sNDA For Oral VENCLEXTA Combo Regimen In CLL Treatment
|
Jul 29
|
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
|
Jul 29
|
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
|
Jul 28
|
HS market forecast to reach $7.8bn across 7MM by 2034
|
Jul 28
|
Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.
|
Jul 28
|
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
|
Jul 28
|
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
|
Jul 28
|
2 Top Dividend Stocks to Buy Right Now and Hold Forever
|
Jul 28
|
Option Volatility And Earnings Report For July 28 – Aug 1
|
Jul 28
|
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
|
Jul 28
|
AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan
|
Jul 26
|
The Smartest Dividend Stocks to Buy With $350 Right Now
|
Jul 26
|
Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
|
Jul 25
|
Mag 7 earnings, Fed meeting, PCE, jobs report: What to Watch
|
Jul 24
|
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
|